Core Viewpoint - Shenzhen Overseas Chinese Town Holdings announced a revised Financing Guarantee Management System aimed at standardizing the company's financing guarantee behavior and enhancing management to prevent cross-transmission of debt risks [1][2] Group 1: Scope and Types of Guarantees - The new system applies to the company and its controlled subsidiaries, with reference to financing guarantees for equity investees [1] - Various forms of financing guarantees are included, such as general guarantees, joint liability guarantees, mortgages, pledges, and implicit guarantees, but do not cover temporary guarantees for mortgage loans provided by real estate companies to homebuyers [1] Group 2: Approval Process and Conditions - Detailed regulations on guarantee approval authority are established, requiring external guarantees to be within the annual guarantee matters approved by the shareholders' meeting, with excess amounts needing board approval [1] - Specific situations, such as a single guarantee exceeding 10% of the company's latest audited net assets, require board approval and subsequent submission to the shareholders' meeting, with a two-thirds majority vote needed for guarantees exceeding 30% of total audited assets in the last twelve months [1] - Guarantees must be approved by more than half of all directors and require a two-thirds majority of attending directors for resolution, with timely external disclosure [1] Group 3: Guarantee Objects and Responsibilities - Each level of enterprise can only guarantee subsidiaries or equity investees with ongoing operational and debt repayment capabilities, prohibiting guarantees for companies lacking such capabilities unless approved by the board or shareholders' meeting [2] - Guarantees must strictly follow shareholding ratios, and any necessary over-shareholding guarantees require approval and counter-guarantees from minority shareholders [2] - The board must understand the situation of the guaranteed party, while the finance department oversees the guarantee work, the legal compliance department handles legal risks, and the board secretary's office is responsible for information disclosure [2] Group 4: Management and Penalties - The system outlines processes for management, post-guarantee management, and penalties, requiring an assessment of the creditworthiness of the guaranteed party before applying for guarantees [2] - Changes to guarantee contract terms require re-approval, and guarantees must be terminated promptly upon expiration [2] - Enterprises must maintain a ledger, manage guarantees according to the "631" principle, monitor the guaranteed party's situation, and pursue timely recovery after fulfilling guarantee responsibilities [2] - Violations will lead to accountability and compensation requirements for responsible individuals [2]

Summary of Key Points Core Viewpoint - The company has decided to cancel a previously approved guarantee of up to 50 million RMB for its subsidiary, which will help in better managing financing guarantees without negatively impacting its operations or long-term interests [1][2]. Group 1: Guarantee Situation Overview - The company approved a financing credit of up to 50 million RMB for its subsidiary, with a joint liability guarantee provided by another subsidiary [1]. - The guarantee was related to a loan application made by Beijing Huasu Pharmaceutical Co., Ltd. to Beijing Bank [1]. Group 2: Cancellation of Guarantee - The cancellation of the 50 million RMB guarantee is aimed at effectively managing the external guarantee limits and aligning with the funding needs of the company and its subsidiaries [2]. - The cancellation will not adversely affect the company's normal operations or business development [2]. Group 3: Total Guarantee Amount and Status - After the cancellation, the total guarantee amount for the company and its subsidiaries stands at 896 million RMB, which is 56.41% of the latest audited net assets and 24.14% of total assets [3]. - The total balance of external guarantees is 552.38 million RMB, accounting for 34.78% of the latest audited net assets, with no overdue guarantees or litigation issues reported [3].

Group 1 - The company held the 15th meeting of the 10th Supervisory Board on June 13, 2025, with all three supervisors participating in the voting, which complied with relevant regulations [2][4] - The Supervisory Board approved the financial write-off of asset losses, with a total original value of inventory and fixed assets amounting to 1,789,961.56 yuan and an estimated loss of 978,888.18 yuan, impacting the total profit for 2024 by 825,135.58 yuan [3][4] - The financial write-off will not affect the company's profit and loss for the year 2025, as the impact has already been accounted for in previous years [3] Group 2 - The company announced the proposed cancellation of its subsidiary, Guangxi Wuzhou Zhongheng Pharmaceutical (Hong Kong) Co., Ltd., during the 29th meeting of the 10th Board of Directors held on June 13, 2025 [7][12] - The reason for the cancellation is that the subsidiary has not engaged in substantial operations since its establishment, and the company aims to optimize its organizational structure and improve operational efficiency [8] - The cancellation will not involve personnel arrangements and is not expected to have a significant impact on the company's financial and operational status [9] Group 3 - The Board of Directors approved the establishment of the "Overseas Investment Management Measures" and the "Financing Guarantee Management Measures," as well as the revision of the "Financing Management System" [13][15][16] - All resolutions passed with unanimous support from the board members, indicating strong consensus on these governance measures [14][15]